RAC Research Primer - June 2020, page-133

Yes it was IMC, at one point 17x.


"The U.S.-listed shares of of Immuron Ltd. IMRN, +852.33% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center (NMRC) has requested a pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding the treatment being developed for severe campylobactcampylobacteriosis and ETEC infections (E-Coli).

The stock was trading at $20.65, or 890.4% above Monday's closing price of $2.10. Trading volume blasted off to 65.5 million shares, compared with the full-day average of about 5,900 shares and nearly 15 times the 4.4 million shares outstanding. "The Australian Importation permit required to ship the vaccines from the NMRC was approved by Biosecurity Australia and the NMRC vaccines were shipped to our contract research partner to commence the project," said Immuron Chief Executive Jerry Kanellos. "The plan is to have the product completed by the end of this year and have it ready for clinical evaluation next year." "